A prospective, claims-based assessment of the risk of pancreatitis and pancreatic cancer with liraglutide compared to other antidiabetic drugs

Aim We evaluated the relationship between liraglutide and acute pancreatitis or pancreatic cancer in an ongoing post‐marketing safety assessment programme. Methods Initiators of liraglutide, exenatide, metformin, pioglitazone or groups containing initiators of dipeptidyl peptidase‐4 inhibitors or su...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Diabetes, obesity & metabolism obesity & metabolism, 2014-03, Vol.16 (3), p.273-275
Hauptverfasser:	Funch, D., Gydesen, H., Tornøe, K., Major-Pedersen, A., Chan, K. A.
Format:	Artikel
Sprache:	eng
Schlagworte:	Antidiabetics Confidence intervals Databases, Factual Diabetes mellitus Dipeptidyl-Peptidase IV Inhibitors - adverse effects Drug development Female GLP-1 Glucagon Glucagon-Like Peptide 1 - adverse effects Glucagon-Like Peptide 1 - analogs & derivatives Health risk assessment Humans Hypoglycemic Agents - adverse effects Insurance Claim Reporting - statistics & numerical data Insurance claims Insurance, Health Liraglutide Male Metformin Metformin - adverse effects observational study Original Pancreas Pancreatic cancer Pancreatic Neoplasms - chemically induced Pancreatitis Pancreatitis - chemically induced pharmaco-epidemiology Pioglitazone Prospective Studies Regression analysis Risk Assessment Sulfonylurea Compounds - adverse effects United States
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!